Drug Information Association Logo
« Back to Listing

National Strategy to Bridge the Gap Between Academic Innovation and Commercialization in Asia

Track:
Project/Portfolio Management and Strategic Planning

Day & Time:
June 17, 10:30AM - 12:00PM (Pacific Standard Time)

Session Number:
231

Room Number:
1A

Level:
Intermediate

Type:
Forum

Title:
National Strategy to Bridge the Gap Between Academic Innovation and Commercialization in Asia

Chair(s):
Herng-Der Chern, MD, PhD
Chief Medical Officer
Supra Integrated and Incubation Center, Taiwan

Description:
There are major funding and drug development know-how gaps in commercialization for translational research in academia. This forum will use three venture capital-like national strategies in Singapore, Korea, and Taiwan to bridge these gaps.

Learning Objective(s):
Discuss the gaps between funding and drug development know-how for commercialization in translational medicine; Describe national strategies and measures to bridge the gap using an approach like venture capital; Compare the similarities and differences among three models in Asia - namely D3 Singapore, KDDF Korea, and SIIC Taiwan.

Presentation(s) & Speaker(s):
The Stanford SPARK Model
Daria Mochly-Rosen
Professor, Co-Director of SPARK
Stanford University, United States

Singapore's D3 Model
Louise Sarup, PhD
Head of Business Development and Licensing
D3, A*STAR, Singapore